End-of-life targeted degradation of DAF-2 insulin/IGF-1 receptor promotes longevity free from growth-related pathologies

Preferably, lifespan-extending therapies should work when applied late in life without causing undesired pathologies. Reducing insulin/insulin-like growth factor (IGF)-1 signaling (IIS) increases lifespan across species, but the effects of reduced IIS interventions in extreme geriatric ages remains...

Descripción completa

Detalles Bibliográficos
Autores principales: Venz, Richard, Pekec, Tina, Katic, Iskra, Ciosk, Rafal, Ewald, Collin Yvès
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2021
Materias:
Developmental Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492056/
https://www.ncbi.nlm.nih.gov/pubmed/34505574
http://dx.doi.org/10.7554/eLife.71335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8492056/
https://www.ncbi.nlm.nih.gov/pubmed/34505574
http://dx.doi.org/10.7554/eLife.71335

Ejemplares similares